e-learning
resources
Virtual 2020
Pre-Congress Content
Clinical and laboratory pharmacology in asthma
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Indacaterol/mometasone furoate combination: synergism in human hyperresponsive airway smooth muscle
L. Calzetta (Rome, Italy), B. Ritondo (Rome, Italy), I. Nikolaev (Basel, Switzerland), M. Cazzola (Rome, Italy), M. Matera (Naples, Italy), P. Rogliani (Rome, Italy)
Source:
Virtual Congress 2020 – Clinical and laboratory pharmacology in asthma
Session:
Clinical and laboratory pharmacology in asthma
Session type:
E-poster session
Number:
1416
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
L. Calzetta (Rome, Italy), B. Ritondo (Rome, Italy), I. Nikolaev (Basel, Switzerland), M. Cazzola (Rome, Italy), M. Matera (Naples, Italy), P. Rogliani (Rome, Italy). Indacaterol/mometasone furoate combination: synergism in human hyperresponsive airway smooth muscle. 1416
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Respiratory sequelae of preterm birth across the life span
Related content which might interest you:
A comparison of beta
2
-adrenoceptor desensitisation induced by olodaterol and formoterol in human lung mast cells and airway smooth muscle cells
Source: Annual Congress 2013 –New drugs in respiratory medicine
Year: 2013
Inhaled budesonide induces corticosteroid-dependent gene expression in asthmatics: Validation in primary epithelial and airways smooth muscle cells
Source: Annual Congress 2011 - Models of disease and drug actions
Year: 2011
Effects of fluticasone and salmeterol on cytokine-induced airway smooth muscle IP10 release
Source: Eur Respir J 2005; 26: Suppl. 49, 712s
Year: 2005
The long-acting β2-agonist formoterol re-establishes the anti-proliferative effect of glucocorticoids in asthmatic airway smooth muscle cells (ASMC)
Source: Annual Congress 2011 - Understanding disease and drug mechanisms
Year: 2011
Proliferation is not increased in airway myofibroblasts isolated from asthmatics
Source: Eur Respir J 2008; 32: 362-371
Year: 2008
Inhibition of allergen-induced airway remodelling by tiotropium and budesonide: a comparison
Source: Eur Respir J 2007; 30: 653-661
Year: 2007
Inhibition of IL-8 and RANTES release from cultured human airway smooth muscle cells by fluticasone and budesonide
Source: Eur Respir J 2002; 20: Suppl. 38, 384s
Year: 2002
Budesonide prevents cytokine-induced decrease of the relaxant response to formoterol but not to salmeterol in mouse trachea
Source: Annual Congress 2009 - Translational research/biomarkers
Year: 2009
Endothelin-1-mediated contraction of mouse small airways is resistant to salbutamol, but sensitive to rosiglitazone
Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases
Year: 2013
Mechanisms of bronchial hyperresponsiveness in a clinical setting – putative role of smooth muscle
Source: Annual Congress 2005 - Role of the bronchial smooth muscle in regulating airway disease
Year: 2005
Treating asthma means treating airway smooth muscle cells
Source: Eur Respir J 2008; 32: 265-274
Year: 2008
Beta2-agonists but not glucocorticoids inhibit proliferation of asthmatic airway smooth muscle cells
Source: Eur Respir J 2004; 24: Suppl. 48, 251s
Year: 2004
Impaired inhibitory action of corticosteroids on chemokine expression induced by TNFalpha in airway smooth muscle (ASM) cells from patients with severe asthma
Source: Annual Congress 2013 –Airway smooth muscle and cell biology
Year: 2013
IL-13 induces glucocorticoid-insensitive hyperreactivity of human small airways
Source: International Congress 2015 – Modulating the immune system in COPD and asthma
Year: 2015
Long-term effects of bronchial thermoplasty on airway smooth muscle and collagen deposition in severe asthma
Source: International Congress 2016 – Asthma: from basic mechanisms to novel therapeutic perspectives
Year: 2016
The anti-proliferative effect of hydrogen sulfide upon human airway smooth muscle in COPD
Source: International Congress 2014 – New drugs for asthma, COPD and pulmonary fibrosis
Year: 2014
Effect of nilotinib on airway smooth muscle thickening in a murine model of chronic asthma
Source: Annual Congress 2012 - New drug targets and pre-clinical models for respiratory diseases
Year: 2012
Fevipiprant reduces airway smooth muscle mass in asthmatics via PGD2 receptor antagonism
Source: International Congress 2017 – Novel mechanisms and treatments for asthma
Year: 2017
Involvement of the BK channels/G proteins processes in the synergistic effects between anticholinergic agents and beta
2
-adrenoceptor agonists in airway smooth muscle
Source: Annual Congress 2013 –Novel mechanisms for established drugs for asthma and COPD management
Year: 2013
Inhaled roflumilast and tadalafil supress airway reactivity and inflammation in ovalbumin-sensitized guinea pigs
Source: International Congress 2016 – Preclinical pharmacology: drug targets and mechanisms of action
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept